

## In This Issue: September 21, 2021

## Research

## ORIGINAL INVESTIGATION

**1013 Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial**JJ McNamee and Coauthors  
for the REST Investigators

This randomized clinical trial examines whether lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal, compared with standard care, will decrease mortality 90 days after randomization in patients with acute hypoxemic respiratory failure.

Visual Abstract

**1024 Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial**J Johnstone and Coauthors  
for the Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials Group

This clinical trial assessed whether *Lactobacillus rhamnosus* GG compared with placebo reduces ventilator-associated pneumonia and other clinically important outcomes for a broad range of critically ill patients.

Visual Abstract | CME

**1034 Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Among Patients at Low Surgical Risk**

RR Makkar and Coauthors

This registry-based cohort study compared rates of mortality and stroke at 30 days and 1 year among patients at low surgical risk with bicuspid vs tricuspid aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).

Editorial 1009

## Opinion

## VIEWPOINT

**1001 Confronting the Delta Variant of SARS-CoV-2, Summer 2021**

C del Rio, PN Malani, and SB Omer

Viewpoint 1003

Video

**1003 Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals**

SS Kadri and SQ Simpson

Video

**1005 The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health**

RG Baker, WJ Koroshetz, and ND Volkow

## A PIECE OF MY MIND

**1007 It Is What It Is**

MP Kerlin

In this narrative medicine essay, a critical care physician tells how plans for her sister's kidney transplant halted last year when the COVID-19 pandemic caused the shutdown of most nonurgent medical care services and hopes the system can develop a better process for patients with chronic diseases.

## EDITORIAL

**1009 Transcatheter Valve Replacement for Bicuspid Aortic Stenosis**

CM Otto and DE Newby

Related Article 1034

**1011 A Reporting Guideline for Mediation Analyses**

K Yadav and RJ Lewis

Related Article 1045

## EDITOR'S NOTE

**1057 Reporting Findings From Mediation Analyses**

PB Fontanarosa

Related Article 1045

## Online at JAMA.com

## AUDIO

Editor's Summary of This Issue

9/11 Responders' Health 20 Years Later, Part 1

9/11 Responders' Health 20 Years Later, Part 2

## VIDEO

Frequently Asked COVID-19 Vaccine Questions

Immunosuppression, Chronic COVID-19, and SARS-CoV-2 Variants

## CME

Find CME quizzes online at [jamacmelookup.com](http://jamacmelookup.com)

## INSTRUCTIONS FOR AUTHORS

[jamanetwork.com/pages/for-authors](http://jamanetwork.com/pages/for-authors)

## DEPARTMENTS

Staff Listing 993

CME Questions 1062

Recruitment &amp; Classified Advertising 1111

Contact Information 1115

## CORRECTION 1072

## Interim Editor in Chief

Phil B. Fontanarosa, MD, MBA

Available online

[jama.com](http://jama.com)

continued &gt;



## In This Issue: September 21, 2021

## Clinical Review &amp; Education

## SPECIAL COMMUNICATION

**1045 A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement**H Lee and Coauthors  
and the AGReMA group

This Special Communication describes the methods that were used to develop the guideline, provides a long- and short-form checklist to be used when writing research reports, presents brief explanations for each reporting item, and provides guidance on how to use A Guideline for Reporting Mediation Analyses (AGReMA).

Editorial **1011**Editor's Note **1057**

CME

## JAMA CLINICAL GUIDELINES SYNOPSIS

**1058 Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy**

BA Derman and AM Davis

This JAMA Clinical Guidelines Synopsis summarizes the American Society of Clinical Oncology's 2020 guideline on the prevention and management of chemotherapy-induced peripheral neuropathy in adults.

## FROM THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS

**1060 Pitolisant (Wakix) for Narcolepsy**

This Medical Letter review summarizes the use of pitolisant, a histamine-3-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

## APPENDIX

**1077 MD-Granting Medical Schools in the United States, 2020-2021**

B Barzansky and SI Etzel

**1088 Graduate Medical Education, 2020-2021**

SE Brotherton and SI Etzel

## JAMA PATIENT PAGE

**1116 Pulmonary Hypertension**

K Walter

This JAMA Patient Page describes the 5 different types of pulmonary hypertension and how it is diagnosed and treated.

Available online

## News &amp; Analysis

## MEDICAL NEWS &amp; PERSPECTIVES

**995 Twenty Years After 9/11, Responders Are Still Healing**

J Abbasi

This Medical News article discusses ongoing physical and mental health effects for emergency personnel, recovery and cleanup workers, and volunteers who responded on and after the September 11, 2001, terrorist attacks.

Audio

## GLOBAL HEALTH

**999 Increase in Myopia Reported Among Children During COVID-19 Lockdown****999 India Takes Aim at Eliminating Visceral Leishmaniasis****999 US Health System Ranks Last Among High-Income Countries**

## NEWS FROM THE FOOD AND DRUG ADMINISTRATION

**1000 New Treatment Approved for Adults and Children With Pompe Disease****1000 Lupus Drug Is Approved Despite Previous Clinical Trial Setback****1000 "Collaborative Communities" Tackle Device Development Challenges**

## Humanities

## POETRY AND MEDICINE

**1074 Penned**

R Uzgir

## JAMA REVISITED

**1075 Beethoven's Deafness**

## Letters

## RESEARCH LETTER

**1063 Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses**

I Benotmane and Coauthors

This study examines the antibody responses to a third dose (100 µg) of the mRNA-1273 SARS-CoV-2 vaccine among kidney transplant recipients in France who had not responded to 2 doses of the vaccine.

**1065 Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection**

Z Congrave-Wilson and Coauthors

This study investigates the timeframe that optimizes saliva sensitivity for SARS-CoV-2 detection using reverse transcriptase-polymerase chain reaction (RT-PCR) testing.

## COMMENT &amp; RESPONSE

**Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases****1067** K Papamichail, MC Dubinsky, and AS Cheifetz**1068** TT Serkland, S Skrede, and JA Berg**1069** O Le Tilly, G Paintaud, and D Ternant

## In Reply

**1069** SW Syversen, N Bolstad, and EA Haavardsholm**Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis****1070** C-Y Chen, C-Y Wang, and C-C Lai

## In Reply

**1071** FJ Martinez, KJ Anstrom, and I Noth